. Targeting CB2 receptor with a novel antagonist reverses cognitive decline, neurodegeneration and pyroptosis in a TAU-dependent frontotemporal dementia mouse model. Brain Behav Immun. 2025 Mar 11;127:251-268. Epub 2025 Mar 11 PubMed.

Recommends

Please login to recommend the paper.

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.

AlzAntibodiesAlzBiomarkerAlzRiskBrain BanksGeneticsAlzGeneHEXMutationsProtocolsResearch ModelsTherapeutics